KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.Lancet OncolPMID 39214106无 PMCID2024-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).NeurotherapeuticsPMID 39227284PMC115798732024-Sep0.98未发现恶性肿瘤人群证据。待处理
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study.ESMO OpenPMID 39241495PMC114060802024-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
QL1701 (a proposed trastuzumab biosimilar) versus reference trastuzumab plus docetaxel as first-line therapy for HER2-positive metastatic breast cancer: a multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial.ESMO OpenPMID 39241496PMC114060812024-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation.Clin PharmacokinetPMID 39243304PMC114500612024-Sep0.45The study is a randomized Phase III trial of a drug (asciminib) in human oncology (CML-CP) with original results. However, the primary efficacy endpoint is major molecular response rate (a categorical response rate), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP. The abstract does not mention Kaplan-Meier analysis, hazard ratios, or any time-to-event outcome, so it fails the time-to-event criterion.待处理
Integrated Population Pharmacokinetics of Daprodustat in Patients with Chronic Kidney Disease with Anemia.Clin PharmacokinetPMID 39259485无 PMCID2024-Sep0.98未发现恶性肿瘤人群证据。待处理
Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a Phase 3 randomized, observer-blind, immunobridging trial in the Philippines.J Med VirolPMID 39318203无 PMCID2024-Sep0.98未发现恶性肿瘤人群证据。待处理
Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer.Cancer MedPMID 39325020PMC114261602024-Sep0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II/III trial of JCOG1008.Cancer MedPMID 39348265PMC114413892024-Sep0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial.Nephrol Dial TransplantPMID 38323492PMC113618042024-Aug-300.98未发现恶性肿瘤人群证据。待处理
Implementation and adherence to regular asymptomatic testing in a COVID-19 vaccine trial.VaccinePMID 39060202无 PMCID2024-Aug-300.98未发现恶性肿瘤人群证据。待处理
Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL.BloodPMID 38518104无 PMCID2024-Aug-290.85The record describes a randomized phase II/III trial in oncology with human subjects and drug intervention, but the abstract does not explicitly present a time-to-event efficacy endpoint (e.g., OS, PFS) with KM or HR data; it focuses on genomic prognostic factors.待处理
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases.Nat CommunPMID 39209823PMC113622942024-Aug-290.98未发现恶性肿瘤人群证据。待处理
Evaluating trends in damage to attractive targeted sugar baits (ATSBs) deployed during the second year of a two-year Phase III trial in Western Zambia.Malar JPMID 39210405PMC113633572024-Aug-290.98未发现恶性肿瘤人群证据。待处理
Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis.RMD OpenPMID 39209369PMC113673722024-Aug-280.98未发现恶性肿瘤人群证据。待处理
Cerebral small vessel disease modifies outcomes after minimally invasive surgery for intracerebral haemorrhage.Stroke Vasc NeurolPMID 37949482PMC114209212024-Aug-270.98未发现恶性肿瘤人群证据。待处理
Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor-Positive, HER2-Positive Breast Cancer.J Natl Compr Canc NetwPMID 39191270PMC114730942024-Aug-260.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.LancetPMID 39181597无 PMCID2024-Aug-240.98未发现恶性肿瘤人群证据。待处理
Heterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: relationship between injection need and vision with as-needed ranibizumab.Br J OphthalmolPMID 38290802PMC113472242024-Aug-220.98未发现恶性肿瘤人群证据。待处理
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.N Engl J MedPMID 39167807无 PMCID2024-Aug-220.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Factors influencing fidelity to guideline implementation strategies for improving pain care at cancer centres: a qualitative sub-study of the Stop Cancer PAIN Trial.BMC Health Serv ResPMID 39174979PMC113426882024-Aug-220.90The record describes a qualitative sub-study of a Phase III RCT evaluating implementation strategies for pain care in cancer patients. While the parent trial is oncology-related and randomized, this specific report is a qualitative analysis of factors influencing fidelity and does not report any survival, progression, recurrence, death, or other efficacy outcomes relevant to KM digitization.待处理
Association between matrix metalloprotease-3 levels and radiographic progression in patients with rheumatoid arthritis: A post hoc analysis from a Japanese Phase 3 clinical trial of peficitinib (RAJ4).Mod RheumatolPMID 37902304无 PMCID2024-Aug-200.98未发现恶性肿瘤人群证据。待处理
Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.JAMAPMID 38819983PMC113370712024-Aug-200.98未发现恶性肿瘤人群证据。待处理
Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.J Clin OncolPMID 38824432无 PMCID2024-Aug-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.J Clin OncolPMID 38833658PMC113289232024-Aug-201.00命中用户提供的消化道肿瘤阳性参考集。待处理
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.J Clin OncolPMID 38843511PMC113289202024-Aug-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study.CirculationPMID 38939948无 PMCID2024-Aug-200.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE REGIMEN phase 3 trial.Chin Med J (Engl)PMID 39018121PMC113326982024-Aug-200.99记录类型属于综述、Meta 分析、社论、评论、病例或指南。待处理
HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES.Cell Rep MedPMID 39168093PMC113849522024-Aug-200.85The record describes a subgroup analysis of a Phase III trial, not the original primary result report. Therefore, it is excluded as an original formal-result report.待处理
Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.JAMAPMID 38820549PMC113370702024-Aug-200.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Effect of early administration of tetracosactide on mortality and host response in critically ill patients requiring rescue surgery: a sensitivity analysis of the STOPSHOCK phase 3 randomized controlled trial.Mil Med ResPMID 39160574PMC113317422024-Aug-190.98未发现恶性肿瘤人群证据。待处理
Adverse event assessment in a parenting programme: experiences from a multisite randomised controlled trial.TrialsPMID 39154169PMC113300342024-Aug-170.98未发现恶性肿瘤人群证据。待处理
Seroreversion to Chlamydia trachomatis Pgp3 Antigen Among Children in a Hyperendemic Region of Amhara, Ethiopia.J Infect DisPMID 38134305PMC113268332024-Aug-160.98未发现恶性肿瘤人群证据。待处理
Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.J Infect DisPMID 38349280PMC113268272024-Aug-160.98未发现恶性肿瘤人群证据。待处理
Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study.CancerPMID 38703010无 PMCID2024-Aug-150.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.N Engl J MedPMID 38828946无 PMCID2024-Aug-150.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings.J Acquir Immune Defic SyndrPMID 38985445PMC112362652024-Aug-150.98未发现恶性肿瘤人群证据。待处理
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.Br J DermatolPMID 38366639无 PMCID2024-Aug-140.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.J Crohns ColitisPMID 38613425PMC113243382024-Aug-140.98未发现恶性肿瘤人群证据。待处理
Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.VaccinePMID 38772835PMC113203632024-Aug-130.98未发现恶性肿瘤人群证据。待处理
Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.NeurologyPMID 39018512PMC113149492024-Aug-130.98未发现恶性肿瘤人群证据。待处理
Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial.Signal Transduct Target TherPMID 39134529PMC113194912024-Aug-130.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Measuring treatment impacts on symptoms in adults with hypoparathyroidism: findings from the PaTHway trial.J Patient Rep OutcomesPMID 39136801PMC113224642024-Aug-130.98未发现恶性肿瘤人群证据。待处理
Community acceptance of a novel malaria intervention, Attractive Targeted Sugar Baits, in the Zambia phase III trial.Malar JPMID 39129018PMC113181122024-Aug-120.98未发现恶性肿瘤人群证据。待处理
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.J Clin OncolPMID 38805668PMC113154072024-Aug-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.J Clin OncolPMID 38833659PMC113154032024-Aug-100.95The trial is a randomized Phase III oncology study with a drug intervention and original results, but its primary and secondary efficacy endpoints are binary response rates (complete response, nausea-free), not time-to-event outcomes. Therefore, it does not meet the core eligibility criterion for a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR).待处理
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09).J Clin OncolPMID 38838287无 PMCID2024-Aug-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia.N Engl J MedPMID 38828945无 PMCID2024-Aug-080.98未发现恶性肿瘤人群证据。待处理
Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.N Engl J MedPMID 38828955PMC113099002024-Aug-080.98未发现恶性肿瘤人群证据。待处理
Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial.JAMAPMID 38762797PMC113041182024-Aug-060.98未发现恶性肿瘤人群证据。待处理